Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122947366 | 12294736 | 6 | F | 20140317 | 20160812 | 20160422 | 20160817 | EXP | PHHY2014CA046676 | NOVARTIS | 79.80 | YR | F | Y | 0.00000 | 20160817 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122947366 | 12294736 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | 150 UG, TID | U | 19667 | 150 | UG | TID | ||||||
| 122947366 | 12294736 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, EVERY 30 DAYS | U | 0 | 30 | MG | /month | ||||||
| 122947366 | 12294736 | 3 | C | TAPAZOLE | METHIMAZOLE | 1 | Unknown | 5 MG, QD | U | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122947366 | 12294736 | 1 | Neuroendocrine carcinoma |
| 122947366 | 12294736 | 2 | Neuroendocrine carcinoma |
| 122947366 | 12294736 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122947366 | 12294736 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122947366 | 12294736 | Asthenia | |
| 122947366 | 12294736 | Basedow's disease | |
| 122947366 | 12294736 | Blood pressure diastolic decreased | |
| 122947366 | 12294736 | Blood pressure increased | |
| 122947366 | 12294736 | Blood pressure systolic increased | |
| 122947366 | 12294736 | Body temperature decreased | |
| 122947366 | 12294736 | Disorientation | |
| 122947366 | 12294736 | Dizziness | |
| 122947366 | 12294736 | Dyspnoea | |
| 122947366 | 12294736 | Fatigue | |
| 122947366 | 12294736 | Gait disturbance | |
| 122947366 | 12294736 | Headache | |
| 122947366 | 12294736 | Hypoaesthesia | |
| 122947366 | 12294736 | Injection site pain | |
| 122947366 | 12294736 | Movement disorder | |
| 122947366 | 12294736 | Pain in extremity | |
| 122947366 | 12294736 | Rash | |
| 122947366 | 12294736 | Sciatica | |
| 122947366 | 12294736 | Sleep disorder due to general medical condition, insomnia type |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122947366 | 12294736 | 1 | 20110325 | 0 | ||
| 122947366 | 12294736 | 2 | 20110408 | 0 |